LONDON — Vutrisiran, a gene-silencing drug, led to impressive reductions in all-cause death and recurrent cardiovascular events in patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) in the HELIOS-B trial, suggesting that patients with this fatal disease will soon have a second drug class to slow progression…
